JAK2 and triple-negative breast carcinoma: In particular, previous studies have shown that nintedanib modulates STAT3 activity, resulting in the apoptosis of triple-negative breast cancer cells [19] as well as ameliorates IPF by inhibiting the JAK2/STAT3 pathway [44].